JP Morgan Chase’s bluebird bio BLUE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-26,870
Closed -$131K 7093
2025
Q1
$131K Sell
26,870
-23,856
-47% -$143K ﹤0.01% 5436
2024
Q4
$423K Buy
50,726
+19,633
+63% +$172K ﹤0.01% 5129
2024
Q3
$323K Sell
31,093
-695
-2% -$11.6K ﹤0.01% 5161
2024
Q2
$626K Sell
31,788
-64,866
-67% -$1.3M ﹤0.01% 4558
2024
Q1
$2.47M Buy
96,654
+8,862
+10% +$227K ﹤0.01% 3681
2023
Q4
$2.42M Buy
87,792
+4,253
+5% +$259K ﹤0.01% 3688
2023
Q3
$5.08M Sell
83,539
-4,677
-5% -$329K ﹤0.01% 2841
2023
Q2
$5.8M Buy
88,216
+25,968
+42% +$1.9M ﹤0.01% 2748
2023
Q1
$3.96M Sell
62,248
-2,404
-4% -$275K ﹤0.01% 3008
2022
Q4
$8.95M Buy
64,652
+3,308
+5% +$466K ﹤0.01% 2361
2022
Q3
$7.77M Sell
61,344
-23,930
-28% -$2.71M ﹤0.01% 2364
2022
Q2
$7.06M Sell
85,274
-7,953
-9% -$617K ﹤0.01% 2462
2022
Q1
$9.04M Sell
93,227
-17,569
-16% -$2.32M ﹤0.01% 2472
2021
Q4
$22.1M Sell
110,796
-38,408
-26% -$9.06M ﹤0.01% 1741
2021
Q3
$36.9M Buy
149,204
+23,410
+19% +$6.69M ﹤0.01% 1339
2021
Q2
$52.1M Buy
125,794
+41,268
+49% +$16.3M 0.01% 1204
2021
Q1
$33M Buy
84,526
+35,327
+72% +$17.4M ﹤0.01% 1387
2020
Q4
$27.6M Buy
49,199
+33,049
+205% +$20.9M ﹤0.01% 1398
2020
Q3
$11.5M Buy
16,150
+1,526
+10% +$1.19M ﹤0.01% 1927
2020
Q2
$11.6M Buy
14,624
+3,678
+34% +$2.77M ﹤0.01% 1782
2020
Q1
$6.52M Buy
10,946
+3,304
+43% +$3.22M ﹤0.01% 2058
2019
Q4
$8.69M Buy
7,642
+2,480
+48% +$2.7M ﹤0.01% 2228
2019
Q3
$6.14M Buy
5,162
+674
+15% +$1.03M ﹤0.01% 2518
2019
Q2
$7.21M Sell
4,488
-206
-4% -$356K ﹤0.01% 2355
2019
Q1
$9.57M Buy
4,694
+823
+21% +$1.45M ﹤0.01% 2096
2018
Q4
$4.97M Sell
3,871
-102
-3% -$156K ﹤0.01% 2579
2018
Q3
$7.51M Sell
3,973
-4,934
-55% -$10.2M ﹤0.01% 2433
2018
Q2
$18.1M Sell
8,907
-1,319
-13% -$3.01M ﹤0.01% 1672
2018
Q1
$22.6M Buy
10,226
+5,012
+96% +$12.7M ﹤0.01% 1428
2017
Q4
$12M Buy
5,214
+1,073
+26% +$2.18M ﹤0.01% 1973
2017
Q3
$7.57M Sell
4,141
-125
-3% -$175K ﹤0.01% 2218
2017
Q2
$5.8M Sell
4,266
-1,151
-21% -$1.39M ﹤0.01% 2379
2017
Q1
$6.38M Sell
5,417
-6,801
-56% -$6.94M ﹤0.01% 2264
2016
Q4
$9.77M Buy
12,218
+4,684
+62% +$3.72M ﹤0.01% 1925
2016
Q3
$6.61M Buy
7,534
+954
+14% +$691K ﹤0.01% 2049
2016
Q2
$3.69M Buy
6,580
+1,977
+43% +$1.12M ﹤0.01% 2474
2016
Q1
$2.54M Buy
4,603
+302
+7% +$185K ﹤0.01% 2575
2015
Q4
$3.58M Sell
4,301
-717
-14% -$716K ﹤0.01% 2424
2015
Q3
$5.56M Sell
5,018
-4,504
-47% -$8.21M ﹤0.01% 2155
2015
Q2
$20.8M Sell
9,522
-1,433
-13% -$2.92M ﹤0.01% 1389
2015
Q1
$17.1M Buy
10,955
+450
+4% +$594K ﹤0.01% 1534
2014
Q4
$12.5M Buy
10,505
+5,875
+127% +$3.93M ﹤0.01% 1792
2014
Q3
$2.15M Buy
+4,630
New +$2.14M ﹤0.01% 2885
2013
Q4
Sell
-975
Closed -$341K 4092
2013
Q3
$341K Buy
+975
New +$362K ﹤0.01% 3813

Other funds holding BLUE

JP Morgan Chase's BLUE Position: Q2 2025 in Review

JP Morgan Chase sold out of bluebird bio (BLUE) in Q2 2025, closing a stake of 26,870 shares — an estimated $131K sold.

JP Morgan Chase first reported a position in BLUE in Q3 2013 and held it in 44 quarters. The position peaked at $52.1M in Q2 2021. 3 funds tracked by Wall St. Rank hold BLUE as of Q2 2025.

  • JP Morgan Chase reported no remaining bluebird bio position as of Q2 2025 after selling out during the quarter.
  • JP Morgan Chase sold 26,870 bluebird bio shares in Q2 2025, an estimated $131K.
  • JP Morgan Chase first reported a position in bluebird bio in Q3 2013 and held it in 44 quarters.
  • JP Morgan Chase's bluebird bio position peaked at $52.1M in Q2 2021.
  • 3 funds tracked by Wall St. Rank held bluebird bio as of Q2 2025.

Based on JP Morgan Chase's 13F filing for Q2 2025, filed 12 Aug 2025.